UNSPSC 51373461: Hydrocodone/carbinoxamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373461 Hydrocodone/carbinoxamine/pseudoephedrine is a Commodity code nominally identifying a specific pharmaceutical combination, but recent state and local solicitations under this code actually cover a broader range of pharmaceuticals and over-the-counter products, including naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. State and local governments purchasing under this code are acquiring pharmaceutical products for public health and community health initiatives, with distribution through authorized wholesalers and delivery to county health facilities and state agency networks. The issuing bodies include county governments (Seminole County, Florida) and state purchasing consortiums operating on behalf of multiple state and local members (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement). Recent solicitations emphasize cGMP certification, FDA compliance, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with authorized wholesale distributors.

Geographic activity centers on Florida and Minnesota, with MMCAP's reach extending to participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS, issued June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023; and MMCAP's RFP S1070000015802, posted January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products supplied through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with proposals due March 26, 2026. Vendors responding to MMCAP must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and must agree to a 3 percent administrative fee on all contract purchases with performance penalties ranging from $200 to $1,500 per violation.